R. Verpoorte, “Exploration of Nature’s Chemodiversity: The Role of secondary Metabolites as Leads in Drug Development,” Drug Discovery Today, Vol. 3, No. 5, 1998, pp. 232-238. doi:10.1016/S1359-6446(97)01167-7

has been cited by the following article:

• TITLE: CuradermBEC5 for Skin Cancers, Is It? An Overview

  AUTHORS: Tania Robyn Chase

  KEYWORDS: Nonmelanoma Skin Cancers, Solasodine Rhamnosyl Glycosides, Curaderm, Solamargine, Solasonine

  JOURNAL NAME: Journal of Cancer Therapy, Vol.2 No.5, December 31, 2011

  ABSTRACT: Skin cancer incidence is increasing at alarming rates and is considered by some as an epidemic. Its incidence is higher than all other cancers combined. The developments of new treatments have not parallelled the increased incidences of this disease. A variety of treatments are available with differing outcomes. More recently a novel topical treatment, consisting of the antineoplastic compounds solasodine rhamnosyl glycosides, solamargine and solasonine, which are derived from plant material, has been described that claims to have many advantages over the currently used skin cancer therapies. This review investigates such claims.